Catalent Collaborates with Moderna
The companies will collaborate the manufacture of personalized cancer vaccines.
On Oct. 13, 2016 Catalent Pharma Solutions announced that it has entered into an agreement with Moderna Therapeutics to support near-term clinical GMP messenger RNA (mRNA) manufacturing efforts for Phase 1/2 clinical studies. The clinical studies will focus on Moderna’s mRNA personalized cancer vaccines.
Moderna is working in collaboration with Merck to advance mRNA-based personalized cancer vaccines for patients across a spectrum of cancers. Clinical studies of of the vaccines are expected to begin in 2017. Under the terms of the agreement, in place through 2018, Moderna will leverage Catalent’s manufacturing capabilities at its facility in Madison, Wisconsin, to support cGMP manufacturing of its mRNA personalized cancer vaccine clinical studies while the company builds out and transitions to its recently announced GMP mRNA clinical manufacturing facility in Norwood, Massachusetts.
Completed in June 2013, Catalent’s Madison facility was designed for both flexible cGMP and non-GMP production. The site features single-use technologies and unidirectional flow to maximize efficiency and safety.
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
